GSK acquires full rights to mRNA candidate vaccines Posted on July 3, 2024July 3, 2024Author Bernice MilesPosted in London Stock ExchangeLeave a Reply GSK acquires full rights to develop, manufacture and commercialise globally mRNA candidate vaccines for influenza and COVID-19, including combinations